

## Preface

Vaccine research and development historically has been a priority for the National Institute of Allergy and Infectious Diseases (NIAID). This area has received renewed emphasis over the past year because of the resurgence of previously declining diseases, the continued emphasis on vaccine safety, and the focus on translating technological advances into improving the health of children through the development of children's vaccines. Immunization experience has shown that vaccines are critical in controlling health care costs as well as in preventing disease and death.

On March 26, 1993, I convened a Blue Ribbon Panel to assist us in assessing our long-term goals for vaccine research and to recommend priorities for the use of anticipated additional resources for FY 1993 and FY 1994. The expert panel was asked to review key elements of the Institute's vaccine research program and to consider priorities for short-term vaccine research, the role of NIAID in accelerating vaccine development through the use of basic research results, and NIAID's position in facilitating vaccine development by working with industry and other private sector groups.

NIAID is deeply indebted to the members of the Blue Ribbon Panel and to the staff of the Division of Microbiology and Infectious Diseases, especially Dr. John La Montagne. Their efforts are reflected in this report, which was presented for review to the National Advisory Allergy and Infectious Diseases Council at its June 1993 meeting. The report summarizes the discussion of the research program by the panel and outlines a research plan for the near term.

A handwritten signature in black ink, appearing to read 'A. Fauci', with a stylized flourish at the end.

Anthony S. Fauci, M.D.  
Director  
National Institute of Allergy and Infectious Diseases